Despite generic drug makers and other threats to biotech and pharmaceutical patents, companies in the industry are not backing down. Biotechnology and pharmaceutical companies are seeking help from Congress and the Office of the U.S. Trade Representative to help combat the increasing number of patent validity challenges, as well as law firms to advise on dealing with the growing number of post-grant review proceedings at the Patent Trial and Appeal Board (PTAB).
As of June 30, 2015, PTAB challenges to biotech and pharma patents had nearly doubled in the 2015 fiscal year in comparison to the previous fiscal year. Finnegan attorney Adriana L. Burgy said, "Post-grant proceedings in the U.S. Patent and Trademark Office have emerged as a battleground for pharmaceutical patent challenges in addition to the usual district court venue." So far, the results of the proceedings at the PTAB are mixed and provide examples both in favor of pharmaceutical patent owners and also invalidating pharmaceutical patents. Burgy believes that it is not necessarily the strongest patents that will survive, but it is the patent owners and companies that are able to adjust to the changing landscape that will come out on top.
Press Release
September 11, 2024
Announcement
September 3, 2024
Announcement
Finnegan and Partner Daniel Chung Recognized by The National Law Journal
September 3, 2024
Press Release
Finnegan Named a “True Trailblazer” for Its Continued Commitment to Mansfield Certification Process
August 16, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.